Phenylbutyrate induces cell differentiation and modulates Epstein-Barr virus gene expression in Burkitt's lymphoma cells

Clinical Cancer Research

Volumn 5, Issue 6, 1999, Pages 1509-1516

  Bar Ner, Matia ^a   Thibault, Alain ^c   Tsokos, Maria ^b   Magrath, Ian T ^a   Samid, Dvorit ^c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLBUTYRIC ACID DERIVATIVE; DIFFERENTIATION INDUCING FACTOR; PHENYLACETIC ACID; PHENYLBUTYRIC ACID; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BURKITT LYMPHOMA; CANCER CELL CULTURE; CANCER INHIBITION; CELL DIFFERENTIATION; CONTROLLED STUDY; ELECTRON MICROSCOPY; HUMAN; HUMAN CELL; IMMUNOGENICITY; ONCOGENE C MYC; PRIORITY JOURNAL;

BURKITT LYMPHOMA; CELL DIFFERENTIATION; CELL DIVISION; CELL SIZE; DNA, VIRAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; GENE EXPRESSION; GENE EXPRESSION REGULATION, VIRAL; HERPESVIRUS 4, HUMAN; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; PHENYLBUTYRATES; TUMOR CELLS, CULTURED; UP-REGULATION; VIRAL MATRIX PROTEINS; VIRUS ACTIVATION;

EID: 0033024624     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Magrath, I. T. African Burkitt's lymphoma. History, biology, clinical features, and treatment. Am. J. Pediatr. Hematol. Oncol., 13: 222-226, 1991.
2. Chang, K. L., and Weiss, L. M. The association of the Epstein-Barr virus with malignant lymphorna. Biomed. Pharmacother., 50: 459-467, 1996.
3. Straus, D. J. Treatment of Burkitt's lymphoma in HIV-positive patients. Biomed. Pharmacother., 50: 447-450, 1996.
4. Bhatia, K., Huppi, K., Spangler, G., Siwarski, D., Iyer, R., and Magrath, I. Point mutations in the c-Myc transactivation domain are common in Burkitt's lymphoma and mouse plasmacytomas. Nat. Genet., 5: 56-61, 1993.
5. Hotchin, N. A., Allday, M. J., and Crawford D. H. Deregulated c-myc expression in Epstein-Barr virus-immortalized B-cells induces altered growth properties and surface phenotype but not tumorigencity. Int. J. Cancer, 45: 566-571, 1990.
6. Ernberg, I. Epstein-Barr virus latency and activation in vivo. Curr. Top. Microbiol., 166: 337-346, 1990.
7. Rowe, M., Rowe, D. T., Gregory, C. D., Young, L. S., Farrell, P. J., Rupani, H., and Rickinson, A. B. Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells. EMBO J., 6: 2743-2751, 1987.
8. de Campos-Lima, P. O., Torsteinsdottir, S., Cuomo, L., Klein, G., Sulitzeanu, D., and Masucci, M. G. Antigen processing and presentation by EBV-carrying cell lines: cell-phenotype dependence and influence of the EBV-encoded LMP1. Int. J. Cancer, 53: 856-862, 1993.
9. Schendel, D. J., Reinhardt, C., Nelson, P. J., Maget, B., Pullen, L., Bornkamm, G. W., and Steinle, A. Cytotoxic T lymphocytes show HLA-C-restricted recognition of EBV-bearing cells and allorecognition of HLA class I molecules presenting self-peptides. J. Immunol., 149: 2406-2414, 1992.
10. Masucci, M. G., Torsteindottir, S., Colombani, J., Brautbar, C., Klein, E., and Klein, G. Down-regulation of class I HLA antigens and of the Epstein-Barr virus-encoded latent membrane protein in Burkitt's lymphoma lines. Proc. Natl. Acad. Sci., 84: 4567-4571, 1987.
11. McManaway, M. E., Neckers, L. M., Loke, S. L., al-Nasser, A. A., Redner, R. L., Shiramizu, B. T., Goldschmidts, W. L., Huber, B. E., Bhatia, K., and Magrath, I. T. Tumour-specific inhibition of lymphoma growth by an antisense oligodeoxynucleotide. Lancet, 335: 808-811, 1990.
12. Anisimova, E., Prachova Roubal, J., and Vonka, V. Effects of n-butyrate and phorbol ester (TPA) on induction of Epstein-Barr virus antigens and cell differentiation. Arch. Virol., 84: 223-237, 1984.
13. Polack, A., Eick, D., Koch, E., and Bornkamm, G. W. Truncation does not abrogate transcriptional down-regulation of the c-myc gene by sodium butyrate in Burkitt's lymphorna cells. EMBO J., 6: 2959-2964, 1987.
14. Luka, J., Kallin, B., and Klein, G. Induction of the Epstein-Barr virus (EBV) cycle in latently infected cells by n-butyrate. Virology, 94: 228-231, 1979.
15. Saemundsen, A. K., Kallin, B., and Klein, G. Effect of n-butyrate on cellular and viral DNA synthesis in cells latently infected with Epstein-Barr virus. Virology, 107: 557-561, 1980.
16. Contreras-Salazar, B., Ehlin-Henriksson, B., Klein, G., and Masucci, M. G. Up-regulation of the Epstein-Barr virus (EBV)-encoded membrane protein LMP in the Burkitt's lymphoma line Daudi after exposure to n-butyrate and after EBV superinfection. J. Virol., 64: 5441-5447, 1990.
17. Samid, D., Shack, S., and Sherrnan, L. T. Phenylacetate. A novel nontoxic inducer of tumor cell differentiation. Cancer Res., 52: 1988-1992, 1992.
18. Liu, L., Shack, S., Stetler-Stevenson, W. G., Hudgins, W. R., and Samid D. Differentiation of cultured human melanoma cells induced by the aromatic fatty acids phenylacetate and phenylbutyrate. J. Invest. Dermatol., 103: 335-340, 1994.
19. Thibault, A., Cooper, M. R., Figg, W. D., Venzon, D. J., Sartor, A. O., Tompkins, A. C, Weinberger, M. S., Headlee, D. J., McCall, N. A., Samid, D, and Meyrs, C. E. A phase I and pharmacokinetic study of intravenous phenylacetate in patients with cancer. Cancer Res., 54: 1690-1694, 1994.
20. Thibault, A., Figg, W. D., and Samid, D. A phase I study of the differentiating agent phenylbutyrate in patients with cancer. Proc. Am. Soc. Clin. Oncol., 15: 484-491, 1996.
21. Samid, D., Yeh, A., and Prasanna, P. Induction of erythroid differentiation and fetal hemoglobin production human leukemic cells treated with phenylacetate. Blood, 80: 1576-1581, 1992.
22. Gore, S. D., Samid, D., and Weng, L-J. Impact of the putative differentiating agents sodium phenylbutyrate and sodium phenylacetate on proliferation, differentiation, and apoptosis of primary neoplastic myeloid cells Clin. Cancer Res., 3: 1755-1762, 1997.
23. Samid, D., Ram, Z., Hudgins, W. R., Shack, S., Liu, L., Walbridge, S., Oldfield, E. H., and Myers, C. E. Selective activity of phenylacetate against malignant gliomas: resemblance to fetal brain damage in phenylketonuria. Cancer. Res., 54: 891-895, 1994.
24. Samid, D., Sonsoles, S., and Myers, C. E. Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by nontoxic pharmacological concentrations of phenylacetate. J. Clin. Invest., 91: 2288-2295, 1993.
25. Call, T. G., Stenson, M. J., and Witzig, T. E. Effects of phenylacetate on cells from patients with B-chronic lymphocytic leukemia. Leuk. Lymphoma, 14: 145-149, 1994.
26. Carducci, M. A., Nelson, J. B., Chan-Tack, K. M., Ayyagari, S. R., Sweatt, W. H., Campbell, P. A., Nelson, W. G., and Simons, J. W. Phenylbutyrate induces apoptosis in human prostate cancer and is more potent than phenylacetate. Clin. Cancer Res., 2: 379-387, 1996.
27. Shack, S., Miller, A., Liu, L., Prasanna, P., Thibault, A., and Samid, D. Vulnerability of multidrug-resistant tumor cells to the aromatic fatty acids phenylacetate and phenylbutyrate. Clin. Cancer Res., 2: 865-872, 1996.
28. Pineau, T., Hudgins, R., Liu, L., Chen, L., Sher, T., Gonzalez, F. J., and Samid, D. Activation of a human peroxisome proliferator-activated receptor by the antitumor agent phenylacetate and its analogs. Biochem. Pharmacol., 52: 659-667, 1996.
29. Magrath, I. T., Freeman, C. B., Pizzo, P., Gadek, J., Jaffe, E., Santaella, M., Hammer, C., Frank, M., Reaman, G., and Novikovs, L. Characterization of lymphoma-derived cell lines: comparison of cell lines positive and negative for Epstein-Barr virus nuclear antigen. II. Surface markers. J. Natl. Cancer Inst., 64: 477-483, 1980.
30. Spira, G., Koide, N., Aman, P., Ber, R., and Klein, G. Truncated μ chain in a Burkitt's lymphoma line (P3HR-1) and its fate in various hematopoietic somatic cell hybrids. Immunohiology, 762: 199-209, 1982.
31. Klein, E., Klein, G., Nadkarni, J. S., Nadkarni, J. J., Wigzell, H., and Clifford, P. Surface IgM-κ specificity on a Burkitt's lymphoma cell in vivo and in derived culture lines. Cancer Res., 28: 1300-1310, 1968.
32. Guy, K., Middleton, P. G., and Steel, C. M. Variant sublines of the human B-lymphoma cells Namalwa are at different stages of differentiation. Immunology, 61: 383-386, 1987.
33. Sambrook, J., Fritsch, E. F., and Maniatis, T. Molecular Cloning: A Laboratory Manual, Ed. 2. Cold Spring Harbor, New York: Cold Spring Harbor Laboratory, 1989.
34. Shiramizu, B., Barriga, F., Neequaye, J., Jafri, A., Dalla-Favera, R., Neri, A., Guttierez, M., Levine, P., and Magrath, I. Patterns of chromosomal breakpoint locations in Burkitt's lymphoma: relevance to geography and Epstein-Barr virus association. Blood, 77: 1516-1526, 1991.
35. Cowan, E. P., Jelachich, M. L., Biddison, W. E., and Coligan, J. E. DNA sequence of HLA-A11: remarkable homology with HLA-A3 allows identification of residues involved in epitopes recognized by antibodies and T cells. Immunogenetics, 25: 241-250.
36. Taylor, N., Countryman, J., Rooney, C., Katz, D., and Miller, G. Expression of the BZLF1 latency-disrupting gene differs in standard and defective Epstein-Barr viruses. J. Virol., 63: 1721-1728, 1989.
37. Gutierrez, M. I., Bhatia, K., and Magrath, I. Replicative viral DNA in Epstein-Barr virus associated Burkitt's lymphoma biopsies. Leuk. Res., 17: 285-289, 1993.
38. Gregory, C. D., Rowe, M., and Rickinson, A. B. Different Epstein-Barr virus-B cell interactions in phenotypically distinct clones of a Burkitt's lymphoma cell line. J. Gen. Virol., 71: 1481-1495, 1990.
39. Rottleb, C., Bornkamm, G. W., and Polack, A. Among 17 inducers of differentiation only sodium butyrate causes a permanent down-regulation of c-myc in Burkitt's lymphoma. Int. J. Cancer, 62: 697-702, 1995.
40. Nagoya, T., and Hinuma, Y. Production of infective Epstein-Barr virus in a Burkitt's lymphoma cell line, P3HR-1. Gann. 63: 87-93, 1972.
41. Moar, M. H., and Klein, G. Abortive expression of the Epstein-Barr virus (EBV) cycle in a variety of EBV DNA-containing cell lines, as reflected by nucleic acid hybridization in situ. Int. J. Cancer, 24: 679-687, 1979.
42. Raab-Traub, N., and Flynn, K. The structure of the termini of the Epstein-Barr virus as a marker of clonal cellular proliferation. Cell, 47: 883-889, 1986.
43. Lenardo, M., Rustgi, A. K., Schievella, A. R., and Bernards, R. Suppression of MHC class I gene expression by N-myc through enhancer inactivation. EMBO J., 8: 3351-3355, 1989.
44. Kitoh, T., Kubota, M., Takimoto, T., Hashimoto, H., Shimizu, T., Sano, H., Akiyama, Y., and Mikawa, H. Metabolic basis for differential glutamine requirements of human leukemia cell lines. J. Cell. Physiol., 143: 150-153, 1990.
45. Hudgins, W. R., Fibach, E., Safaya, S., Rieder, R. F., Miller, A. C., and Samid, D. Transcriptional up-regulation of γ-globin by phenylbutyrate and analogous aromatic fatty acids. Biochem. Pharmacol., 52: 1227-1233, 1996.
46. Robertson, K. D., Hayward, D., Ling, P. D., Samid, D., and Ambinder, R. F. Transcriptional activation of the Epstein-Barr virus latency C promoter after 5-Azacytidine treatment: evidence that demethylation at a single CpG site is crucial. Mol. Cell. Biol., 15: 6150-6159, 1995.
47. Samid, D., Wels, M., Kulkarni, M., Liu, L., and Thibault, A., The nuclear receptors PPARs as novel targets in differentiation therapy: experience with phenylacetate and phenylbutyrate. Anticancer Res., 17: 3927-3928, 1997.
48. Warrell, R. P., He, L-Z., Richon, V., Calleja, E., and Pandolfi, P. P. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J. Natl. Cancer Inst., 90: 1621-1625, 1995.
49. Carducci, M., Bowling, M., Eisenberger, M., Sinibaldi, V., Chen, T-L., Buckley, N., Grochow, L., Noe, D., and Donehower, R. Proc. Am. Soc. Clin. Oncol., 17: 831, 1998.
50. Gore, S. D., Miller, C. B., Weng, L. J., Burks, K., Griffen, C. A., Chen, T. L., Burke, P. J., Grever, M., and Rowinsky, E. K. Improved hematopoiesis in patients with myelodysplastic syndromes and acute myeloid leukemia following administration of the putative differentiating agent sodium phenylbutyrate. Blood, 88: 582a, 1996.
51. Young, C., Malkin, M., Lieberman, F., Tong, W., Krol, G., and Fleischauer, A. A phase I and clinical pharmacokinetic study of intravenous sodium phenylbutyrate, given on a twice daily infusion schedule. Proc. Am. Soc. Clin. Oncol., 16: 255a, 1997.
52. Serabe, B., Adamson, P., Jakacki, R., Berg, S., Parker, R., Balis, F. M., Murry, D. J., Wolfe., R., and Blaney, S. Phase I trial and pharmacokinetic study of sodium phenylbutyrate in children with refractory cancer. Int. Symp. Pediatr. Neuro-Oncol., 8: 28, 1998.